Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma
Share Talk Weekly Stock Market News, 27th July 2019
Share Talk was back in London this week on business and we held a few meeting with listed companies, some of the market sectors are currently struggling in the small-cap
Tiziana Life Sci PLC (NASDAQ:TLSA LON:TILS) Dr Kunwar Shailubhai, CEO & CSO
Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma.
